Abstract
Cardiac contractility modulation (CCM) is a new therapy that has shown promising results in heart failure with preserved ejection fraction (HFpEF) management. This therapy involves the use of a device that delivers electrical signals to the heart during the refractory period, enhancing cardiac contractility without changing heart rate or rhythm. This short article explores the potential of CCM as a new horizon in the management of HFpEF, highlighting its mechanism of action, clinical trials, and future directions for research. Overall, CCM has emerged as a promising therapy for improving the outcomes of patients with HFpEF and provides hope for the development of more effective treatments in the future.